<DOC>
	<DOC>NCT02468284</DOC>
	<brief_summary>The purpose of this trial is to look at how much a new trial drug get into body, such as when the drug concentration in your body reaches peak and how high the peak value is.</brief_summary>
	<brief_title>Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated Has a Prostatespecific Antigen (PSA) level ≥2.0 ng/mL at Screening Has a screening serum testosterone level &gt;150 ng/dL Has an Eastern Cooperative Oncology Group (ECOG) score of ≤2 Has had previous or is currently under hormonal management of prostate cancer. However, hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to the Screening Visit Is currently treated with a 5alpha reductase inhibitor Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy Is in need of neoadjuvant hormonal therapy Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>